Radiotherapy with the anti-programmed cell death ligand-1 immune checkpoint blocker avelumab: acute toxicities in triple-negative breast cancer

Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis?

(2018) Guillaume Louvel et al.   EUROPEAN RESPIRATORY JOURNAL

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

(2018) Jason J. Luke et al.   JOURNAL OF CLINICAL ONCOLOGY

Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis

(2018) Fausto Petrelli et al.   EUROPEAN JOURNAL OF CANCER

Immune checkpoint inhibitor-associated interstitial lung diseases: some progress but still many issues

(2017) David Montani et al.   EUROPEAN RESPIRATORY JOURNAL

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients

(2017) Myriam Delaunay et al.   EUROPEAN RESPIRATORY JOURNAL

Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial

(2017) Narek Shaverdian et al.   LANCET ONCOLOGY

Surgery and radiation therapy of triple-negative breast cancers: From biology to clinics

(2016) Jacques Bernier et al.   BREAST

Pneumonitis and pulmonary fibrosis associated with breast cancer treatments

(2014) Claudia Omarini et al.   BREAST CANCER RESEARCH AND TREATMENT

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

(2014) Patricia Cortazar et al.   LANCET

Multifactorial Approach to Predicting Resistance to Anthracyclines

(2011) Christine Desmedt et al.   JOURNAL OF CLINICAL ONCOLOGY